Table 1.
(Continued).
Hexavalent combination: DTaP = Diphteria, Tetanus and Acellular Pertussis vaccine – paediatric formulation, IPV = Inactivated Polio vaccine, Hep B = Hepatitis B vaccine, Hib = Haemophilus influenzae type b vaccine
MenB = Meningoccal B vaccine, Rotavirus = Rotavirus vaccine
dTap = Diphteria, Tetanus and Acellular Pertussis vaccine – adult/adolescent formulation
dTap-IPV = Diphteria, Tetanus , Acellular Pertussis and Inactivated Polio – adult/adolescent formulation
MMR = Measles, Mumps and Rubella vaccine, MMRV = Measles, Mumps, Rubella and Varicella vaccine, V = Varicella vaccine
PCV = Pneumococcal Conjugate vaccine, PPSV = Pneumococcal polysaccharide vaccine
MenC = Meningococcal C Conjugate vaccine, Men ACWY = Meningococcal ACWY conjugate vaccine
HPV = Human papilloma virus vaccine
Influenza = Influenza vaccine
Hep A = Hepatitis A vaccine
Notes:
*For children born from HBsAg positive mothers four-dose schedule: 1st dose within the first 12-24 hours of life concurrently with specific Hepatitis B immunoglobulins; 2nd dose after 4 weeks, 3rd dose following the lifetime immunization schedule, after the 60th day of (hexavalent vaccine).
Although the final decision should be taken by Regional health administrations according to the local organization of vaccination services, a possible recommended sequence of immunization is the following (the days are suggestive and not mandatory):
Hexavalent vaccine + Pneumococcal vaccine (PCV) at the start of the 3rd month of life (61st day of life)
Meningococcal B vaccine after 15 days (76th day)
Meningococcal B vaccine after 1 month (106th day)
Hexavalent vaccine + Pneumococcal vaccine (PCV) after 15 days, at the start of the 5th month of life (121st day of life)
Meningococcal B vaccine after 1 month, at the start of the 6th month of life (151st day of life)
Hexavalent vaccine + Pneumococcal vaccine (PCV) at the start of the 12th month of life
Meningococcal B vaccine starting from the 13th month of life
Meningococcal C vaccine, always the 1st year of life
Possible co-administration of MMR or MMRV vaccine with Meningococcal C or B vaccine, according to the different regional schedules (see possible combination in the scheme)
In case of co-administration of Meningococcal B vaccine with MMR or MMRV vaccine a counseling service for parents is advisable, with the aim of explaining possible fever occurrence in the hours following vaccination and/or 7-10 days after immunization.
**The third dose must be administered at least 6 months after the second dose. The fourth dose, the last of the first course, must be administered during the 5th–6th year. Use of the adult formulation (dTap) is possible since the 5th year of life if coverage with the 5th dose at adolescence is granted.
***Subsequent booster every 10 years.
*** In response to the outbreaks occurred in the past years, catch-up of the susceptible individuals and an active search of unvaccinated individuals (mop-up) is strongly recommended.
^Individuals without history of varicella: Administration of two doses of vaccine. Second dose at least 4 weeks after the first.
^^Two doses for children who start immunization during the second year of life. One dose only if immunizartion starts during the third year of life.
§One dose. Meningococcal C or Conjugate Men ACWY vaccine is administered at 13-15 months of life. A dose of Men ACWY is recommended at 12-14 years of life both to previously unvaccinated subjects, and to those already immunized as toddlers or children with the MenC or the Men ACWWY conjugate vaccine. Meningococcal C vaccine can be administered to at-risk individuals since the third month of life following a three dose schedule: the third dose should be given T after the 1st year of life.
°Two doses at 0 and 6 months (bivalent and nonovalent vaccine for individuals aged 9-14 years; quadrivalent vaccine for individuals aged 9-13 years), three doses at 0, 1 and 6 months (bivalent) or 0, 2 and 6 months (quadrivalent and nonovalent) for older individuals. A multi-cohort strategy including the cohort of 12-year old males, older female adolescents and/or young women is recommended in order to accelarate HPV diseases prevention. Co-payment at social price of HPV vaccine should be ensured for all those who do not have access to free-of-charge immunization.
°°Immunization with the seasonal vaccine for individuals considered at risk by the Italian Minister of Health and for children who attend kindergartens or other communities. It's recommended to extend Universal offer of free-of-charge vaccination should be extended to all subjects aged ≥50 years.
#Administration is recommended on the basis of age for at least one cohort of individuals ≥60 years and for subjects at risk.
##Universal free of charge offer. Rotavirus vaccine can be co-administred with all other vaccines used in the first months of life.
###Recommendations for highly endemic areas (2 cohorts, at 15/18 months and 12 years). Universal vaccination free of charge for children (0-14 years) who travel abroad.